CClinicalTrials.gg
CompletedNCT03013283InterfaceVentUpdated Jan 27, 2021

CPAP and NIV Interfaces : Side-effects in Home Care Patients

An observational study in Interface, Mask, Continuous Positive Airway Pressure (CPAP) and Non Invasive Ventilation (NIV), sponsored by University Hospital, Montpellier. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by University Hospital, Montpellier · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6,000
Ages
18 Years and older
Sex
All
01

Study summary

Home ventilation techniques consist mainly of two techniques, Continuous Positive Airway Pressure or CPAP and Non Invasive Ventilation or NIV. Whether for CPAP or NIV, pressures are delivered to the patient via an interface.

The efficacy of CPAP and NIV is conditioned in part by the observance of the patients to the device. Because the comfort and degree of satisfaction of the patients to its interface is a key factor of the observance, side-effects and satisfaction of patients need to be continuously evaluated with available interfaces for CPAP and NIV treated patients.

The purpose of the research is the evaluation of interface side-effects and the degree of satisfaction of home care patients treated for at least three months with CPAP or NIV.

Read the detailed description

Home ventilation techniques consist mainly of two techniques, Continuous Positive Airway Pressure or CPAP (the level of pressure delivered being constant) and Non Invasive Ventilation or NIV (pressure level varies from an expiratory pressure to an inspiratory pressure). Whether for CPAP or NIV, pressures are delivered to the patient via an interface. Many manufacturers produce interfaces and these interfaces are the subject of regular technological innovations with the introduction on the market of new product ranges.

Because of the lack of dedicated and actualized studies, there is poor evidence based of difference between old and new interfaces, there is also poor evidence based of differences between manufacturer products.

The efficacy of CPAP and NIV is conditioned in part by the observance of the patients to the device. Because the comfort and degree of satisfaction of the patients to its interface is a key factor of the observance, side-effects and satisfaction of patients need to be continuously evaluated with available interfaces for CPAP and NIV treated patients.

The purpose of the research is the evaluation of interface side-effects and the degree of satisfaction of home care patients treated for at least three months with CPAP or NIV. A visual analog scale is used to assess the patient perception of its interface. A measure of the quality of life and a home care technician evaluation are performed simultaneously. Using the device manufacturer software, a measure of the observance, level of pressure and leak is realised.

A first intermediate analysis will be made after approximately 1000 inclusions (the Sleepileaks (determinants of residual excessive sleapiness), Threshleaks (high leak levels and machine adherence as defined by the American Thoracic Society) and Complileaks studies (all leaks and machine adherence as continuous variables)). A second validating analysis will be made at the end of inclusions.

02

Conditions studied

  • Interface, Mask
  • Continuous Positive Airway Pressure (CPAP)
  • Non Invasive Ventilation (NIV)
  • Hyperventilation Anxiety
  • Sleep Apnea Syndrome (OSAS)
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The patients included in the study corresponded to the annual cohort of patients cared by the APARD home care provider. Patients are were treated with CPAP or VIN for more than 3 months according to the criteria of care and reimbursement of the French Social Security rules.

Inclusion criteria

  • Written informed consent
  • Age more than 18 years (inclusive)
  • Patient treated with CPAP or NIV for at least three months,and eligible for care and for the reimbursement by the French Social Security rules.
  • Patient presents during a scheduled home visit of the technician for the continuation of CPAP or NIV treatment according to the French Social Security rules.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, intention of being pregnant, breastfeeding.
  • Inability to understand the nature and aims of the study or to communicate with the investigator
  • Simultaneous participation in another trial with an exclusion clause to participate to an other trial.
  • No affiliation to the French social security
  • Loss of personal capacity resulting in state protection
  • Deprivation of liberty by judicial or administrative decision
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6,000 participants (actual)
Patient registry
No

Interventions

  • Otherself questionnaire

    * Interface side effects and degree of satisfaction of the patients * Technician evaluation and device measures.

05

What researchers measure

Primary outcomes

  1. Interface side effects and degree of satisfaction of the patients

    During a scheduled home visit of the technician. The primary endpoint is a composite criterion corresponding to the patients' responses to a self-administered questionnaire.

    Time frame: 1 day

Secondary outcomes

  1. Identification by the technician of the problems of pain

    During a scheduled home visit of the technician : Identification by the technician of the problems of pain, erythema and leak, localization of these problems.

    Time frame: 1 day

  2. Percentage of patients with oxygen therapy, heated humidifier, chinstrap.

    During a scheduled home visit of the technician : Percentage of patients with oxygen therapy, heated humidifier, chinstrap.

    Time frame: 1 day

  3. Collection by technician of the type of interface

    During a scheduled home visit of the technician : Collection by technician of the type of interface (nasal pillows, nasal and oronasal, custom made interface), manufacturer name and interface size, type (CPAP/NIV) and manufacturer name of the device.

    Time frame: 1 day

  4. Compliance

    During a scheduled home visit of the technician : Device software data: compliance (hour per day) over the last 3 months

    Time frame: 1 day

  5. Average level of intentional or unintentional leakage

    During a scheduled home visit of the technician : Device software data: average level of intentional or unintentional leakage (l/min)

    Time frame: 1 day

  6. Residual AHI

    During a scheduled home visit of the technician : Device software data: residual AHI (event/hour)

    Time frame: 1 day

  7. Average pressure level and pressure

    During a scheduled home visit of the technician :Device software data: average pressure level and pressure at the 90/95th percentile (cmH2O).

    Time frame: 1 day

  8. Patient quality of life questionnaire

    Patient quality of life questionnaire (EQ-5D 3L, Epworth).

    Time frame: 1 day

  9. Date of first installation of the first ventilation device

    Date of first installation of the first ventilation device

    Time frame: 1 day

  10. Proportion of patient responding to self-help questionnaire without assistance

    Proportion of patient responding to self-help questionnaire without assistance

    Time frame: 1 day

  11. Proportion of patients able to position the interface without assistance

    Proportion of patients able to position the interface without assistance

    Time frame: 1 day

  12. Time taken by the patient and the technician to answer the patient's self-questionnaire and the technician record respectively.

    Time taken by the patient and the technician to answer the patient's self-questionnaire and the technician record respectively.

    Time frame: 1 day

  13. Proportion of patient waiting for a new interface

    Proportion of patient waiting for a new interface

    Time frame: 1 day

  14. Proportion of patients wishing to participate in research on the subject.

    Proportion of patients wishing to participate in research on the subject.

    Time frame: 1 day

06

Study locations

2 sites
  • Centre Hospitalier Universitaire de Montpellier
    Montpellier, 34295, France
  • CHU Saint-Etienne
    Saint-Etienne, 42055, France
07

References and documents

Publications

  • Rotty MC, Mallet JP, Suehs CM, Martinez C, Borel JC, Rabec C, Bourdin A, Molinari N, Jaffuel D. Is the 2013 American Thoracic Society CPAP-tracking system algorithm useful for managing non-adherence in long-term CPAP-treated patients? Respir Res. 2019 Sep 12;20(1):209. doi: 10.1186/s12931-019-1150-7. PubMed 31514751 ↗
  • Rotty MC, Suehs CM, Mallet JP, Martinez C, Borel JC, Rabec C, Bertelli F, Bourdin A, Molinari N, Jaffuel D. Mask side-effects in long-term CPAP-patients impact adherence and sleepiness: the InterfaceVent real-life study. Respir Res. 2021 Jan 15;22(1):17. doi: 10.1186/s12931-021-01618-x. PubMed 33451313 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03013283
Lead sponsor
University Hospital, Montpellier
Responsible party
Sponsor
First posted
Jan 6, 2017
Start date
Feb 7, 2017
Primary completion
Apr 1, 2019
Completion
Apr 1, 2019
Last update
Jan 27, 2021

Study contacts

Dany JAFFUEL, MD, PhD
principal investigator · University Hospital, Montpellier

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion